Latest Regulatory Filings News

Algorae Pharmaceuticals has secured a key Licence & Supply Agreement with Cadila Pharmaceuticals to commercialise two generic cardiovascular and metabolic medicines in Australia and New Zealand, broadening its therapeutic reach beyond oncology.

A single exploration name blew the doors off the leaderboard, while two well-known uranium plays and a Nevada explorer sank hard. Behind the noise: deals got closer to completion, big raisings reset prices, and several “good news” gaps didn’t survive the week.

A single diagnostics update sparked a breakout week, while a handful of biotech names sold off hard despite busy newsflow. Capital raisings, takeover steps and US market pushes kept healthcare in motion heading into mid-February milestones.

A volatile week for ASX tech saw a steep sell-off in freight software, while defence AI and RegTech contract wins pulled buyers back into smaller names. Big corporate actions kept attention on what’s real: signed deals, cash timelines, and who pays whom, and when.

Bridge SaaS Limited has issued a correction to its Appendix 4C quarterly cash flow report, clarifying previously omitted financing facilities without affecting its cash position or operating results.

Memphasys has raised $800,000 through a share placement to accelerate the commercial expansion of its Felix™ System, following key regulatory approvals and initial revenue milestones.

Native Mineral Resources’ board members have converted $1.62 million in options into 63 million new shares, reinforcing their commitment to the company’s growth strategy and key projects in northern Queensland.

WRKR Ltd has completed its strategic acquisition of PaidRight Holdings, issuing over 90 million shares to expand its compliance platform into payroll compliance. This move marks a significant step beyond superannuation, aiming to create a comprehensive compliance solution.

Livium Ltd announces a further A$335,000 distribution from its 50% stake in the LieNA joint venture, following receipt of a substantial R&D tax incentive rebate for FY25. The joint venture remains well-funded through FY27, supporting ongoing lithium extraction technology development.

OncoSil Medical Ltd has launched an $8 million equity raising to fund the commercial expansion and clinical development of its targeted radiotherapy device for pancreatic cancer, aiming to capitalise on growing European market adoption and upcoming trial catalysts.

OncoSil Medical secures $8 million in capital to fund a pivotal German government-sponsored clinical trial and accelerate its European commercial expansion.

Memphasys has lodged regulatory submissions for its Felix™ System in Australia and India, following CE Mark approval, while progressing UK market entry under the CE Mark transition framework.